| LUNG (PULMONARY): MAIN MENU | ||||
|
||||
| Pulmonary Fibrosis | ||||
| This page was written by Shelley Ensz, and has not yet been medically edited. See Disclaimer. | ||||
|
||||
|
||||
| Biologic Agents | ||||
| Biologic agents are biologic response modifying agents that block specific pathways and signals of inflammation. Because of their success with other rheumatic diseases and symptoms, biologics are now be tested for their effectiveness on pulmonary fibrosis. | ||||
| Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. These results indicate that combined inhibition of the tyrosine kinase c-Abl and PDGF receptor might be effective in the later, less inflammatory stages of SSc and for the treatment of established fibrosis. Thus, imatinib might be an interesting candidate for clinical trials in patients with longstanding disease and preexisting tissue fibrosis. Akhmetshina A. (PubMed). Arthritis Rheum. 2009 Jan;60(1):219-24. (Also see: Clinical Trials and Medications) | ||||
| Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. This study suggests that inhibition of TNF-alpha with infliximab may stabilize the progression of pulmonary fibrosis associated with CVD. Prospective, controlled trials are necessary to determine the efficacy of infliximab in pulmonary fibrosis associated CVD. PubMed. Clin Exp Rheumatol. 2007 Jan-Feb;25(1):23-8. (Also see: Medications) |
|
||||||||||||
| Go to Pulmonary Fibrosis Treatments: Cellcept | ||||||||||||
|
||||||||||||